ABSTRACT
The release kinetics of recombinant human bone morphogenic factor 2 (rhBMP-2) from collageneous hydrogel in the presence of human blood plasma have been studied. The expulsion of rhBMP-2 from the collagen-BMP-2 complex by the competitive adhesion of collagen-binding proteins penetrating from plasma was firstly recognized. It was experimentally proven that that blood plasma fibronectin is the main collagen-binding protein, which is responsible for the controlled release of rhBMP-2. As a result, a new collageneous hydrogel with the incorporation of fibronectin was created which retained rhBMP-2 for a twice longer period as compared to the ordinary collageneous hydrogel. A distinctive feature of this new collagen-fibronectin matrix is the slow release of rhBMP-2 in the first three days which allows for the avoiding of adverse effects in clinics caused by the rapid release of large amounts of rhBMP-2 from collageneous hydrogel.
Subject(s)
Bone Morphogenetic Protein 2/chemistry , Collagen/chemistry , Fibronectins/chemistry , Delayed-Action Preparations , Humans , Hydrogels/chemistry , Kinetics , Protein Binding , Recombinant Proteins/chemistry , Tissue Engineering , Tissue ScaffoldsABSTRACT
The results of NSE purification procedure, as well as hybridoma technology of anti NSE monoclonal antibodies synthesis are presented. The employment of this procedure yielded highly purified NSE preparation. The immunization of BALB/C mice with NSE preparation led to sensitization of the immunocompetent cells, which could form hybridomes, producing the anti-NSE monoclonal antibodies, after the confluence with myeloma cells Sp 2/0-Ag 14. The ELISA test-system for NSE analysis was developed on the basis of highly purified NSE preparation and monoclonal anti-NSE antibodies. This system was characterized by high specificity, accuracy and reliability. This system may be recommended for analysis of blood-brain barrier functions in the neurological and psychiatric diseases.
